Roche May Refine Long-Acting EPO Development Based On FDA Advisory Committee Outcome
This article was originally published in The Pink Sheet Daily
Executive Summary
An Oncologic Drugs Advisory Committee meeting on safety issues associated with Amgen's Aranesp and J&J's Procrit could affect the Phase III program for long-acting erythropoietin, Roche says.